KR102768666B1 - Cdk4/6의 활성을 억제하기 위한 화합물의 결정 형태 및 그것의 용도 - Google Patents
Cdk4/6의 활성을 억제하기 위한 화합물의 결정 형태 및 그것의 용도 Download PDFInfo
- Publication number
- KR102768666B1 KR102768666B1 KR1020217001384A KR20217001384A KR102768666B1 KR 102768666 B1 KR102768666 B1 KR 102768666B1 KR 1020217001384 A KR1020217001384 A KR 1020217001384A KR 20217001384 A KR20217001384 A KR 20217001384A KR 102768666 B1 KR102768666 B1 KR 102768666B1
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- crystal form
- cancer
- disease
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2018/092194 | 2018-06-21 | ||
| CN2018092194 | 2018-06-21 | ||
| PCT/CN2019/092239 WO2019242719A1 (zh) | 2018-06-21 | 2019-06-21 | 抑制cdk4/6活性化合物的晶型及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20210024004A KR20210024004A (ko) | 2021-03-04 |
| KR102768666B1 true KR102768666B1 (ko) | 2025-02-17 |
Family
ID=68983152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217001384A Active KR102768666B1 (ko) | 2018-06-21 | 2019-06-21 | Cdk4/6의 활성을 억제하기 위한 화합물의 결정 형태 및 그것의 용도 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12043622B2 (https=) |
| EP (1) | EP3812386A4 (https=) |
| JP (1) | JP7430656B2 (https=) |
| KR (1) | KR102768666B1 (https=) |
| CN (2) | CN112424202B (https=) |
| AU (1) | AU2019290722B2 (https=) |
| BR (1) | BR112020026052A2 (https=) |
| EA (1) | EA202190036A1 (https=) |
| IL (1) | IL279579B2 (https=) |
| MX (1) | MX2020013847A (https=) |
| PH (1) | PH12020552236A1 (https=) |
| SG (1) | SG11202012858QA (https=) |
| TW (1) | TWI786303B (https=) |
| WO (1) | WO2019242719A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117222411B (zh) * | 2021-03-24 | 2026-03-27 | 贝达药业股份有限公司 | 药物组合、包含其的试剂盒及其用途 |
| WO2023131179A1 (zh) * | 2022-01-05 | 2023-07-13 | 贝达药业股份有限公司 | 苯并咪唑衍生物或其盐在治疗白血病中的用途 |
| CN115872923B (zh) * | 2022-12-29 | 2023-04-28 | 成都泰和伟业生物科技有限公司 | 一种化合物及其制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016173505A1 (en) | 2015-04-28 | 2016-11-03 | Shanghai Fochon Pharmaceutical Co., Ltd. | Certain protein kinase inhibitor |
| WO2017071516A1 (zh) | 2015-10-27 | 2017-05-04 | 甘李药业股份有限公司 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
| WO2018113771A1 (en) | 2016-12-22 | 2018-06-28 | Betta Pharmaceuticals Co., Ltd | Benzimidazole derivatives, preparation methods and uses theirof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105294655B (zh) | 2014-07-26 | 2019-03-15 | 广东东阳光药业有限公司 | Cdk类小分子抑制剂的化合物及其用途 |
| CN104592251B (zh) | 2015-01-23 | 2019-10-01 | 上海复星医药产业发展有限公司 | 4-(稠杂环取代氨基)-1h-吡唑-3-甲酰胺类化合物及其用途 |
| WO2017005900A1 (en) | 2015-07-08 | 2017-01-12 | F. Hoffmann-La Roche Ag | ARYL SULTAM DERIVATIVES AS RORc MODULATORS |
| WO2017102796A1 (en) | 2015-12-16 | 2017-06-22 | F. Hoffmann-La Roche Ag | HETEROARYL AMIDE SULTAM DERIVATIVES AS RORc MODULATORS |
| TWI646094B (zh) | 2016-06-01 | 2019-01-01 | 大陸商貝達藥業股份有限公司 | Crystal form of inhibitory protein kinase active compound and application thereof |
| WO2019035008A1 (en) | 2017-08-15 | 2019-02-21 | Beijing Xuanyi Pharmasciences Co., Ltd. | INHIBITORS OF CDK4 / 6 AND THEIR USE |
-
2019
- 2019-06-21 IL IL279579A patent/IL279579B2/en unknown
- 2019-06-21 EA EA202190036A patent/EA202190036A1/ru unknown
- 2019-06-21 EP EP19822566.6A patent/EP3812386A4/en active Pending
- 2019-06-21 US US17/254,097 patent/US12043622B2/en active Active
- 2019-06-21 WO PCT/CN2019/092239 patent/WO2019242719A1/zh not_active Ceased
- 2019-06-21 CN CN201980037275.3A patent/CN112424202B/zh active Active
- 2019-06-21 AU AU2019290722A patent/AU2019290722B2/en active Active
- 2019-06-21 TW TW108121799A patent/TWI786303B/zh active
- 2019-06-21 MX MX2020013847A patent/MX2020013847A/es unknown
- 2019-06-21 KR KR1020217001384A patent/KR102768666B1/ko active Active
- 2019-06-21 CN CN202111208432.8A patent/CN113861191B/zh active Active
- 2019-06-21 JP JP2020571503A patent/JP7430656B2/ja active Active
- 2019-06-21 BR BR112020026052-5A patent/BR112020026052A2/pt unknown
- 2019-06-21 SG SG11202012858QA patent/SG11202012858QA/en unknown
-
2020
- 2020-12-21 PH PH12020552236A patent/PH12020552236A1/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016173505A1 (en) | 2015-04-28 | 2016-11-03 | Shanghai Fochon Pharmaceutical Co., Ltd. | Certain protein kinase inhibitor |
| CN107849012A (zh) | 2015-04-28 | 2018-03-27 | 重庆复创医药研究有限公司 | 一类激酶抑制剂 |
| WO2017071516A1 (zh) | 2015-10-27 | 2017-05-04 | 甘李药业股份有限公司 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
| WO2018113771A1 (en) | 2016-12-22 | 2018-06-28 | Betta Pharmaceuticals Co., Ltd | Benzimidazole derivatives, preparation methods and uses theirof |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3812386A4 (en) | 2022-03-30 |
| IL279579A (en) | 2021-03-01 |
| CA3104365A1 (en) | 2019-12-26 |
| JP2021529175A (ja) | 2021-10-28 |
| EP3812386A1 (en) | 2021-04-28 |
| BR112020026052A2 (pt) | 2021-03-23 |
| AU2019290722B2 (en) | 2023-12-21 |
| IL279579B (en) | 2022-10-01 |
| IL279579B2 (en) | 2023-02-01 |
| CN113861191A (zh) | 2021-12-31 |
| KR20210024004A (ko) | 2021-03-04 |
| CN112424202A (zh) | 2021-02-26 |
| PH12020552236A1 (en) | 2021-06-28 |
| TW202016114A (zh) | 2020-05-01 |
| CN113861191B (zh) | 2023-09-19 |
| US12043622B2 (en) | 2024-07-23 |
| MX2020013847A (es) | 2021-04-28 |
| AU2019290722A1 (en) | 2021-01-28 |
| TWI786303B (zh) | 2022-12-11 |
| CN112424202B (zh) | 2021-09-17 |
| WO2019242719A1 (zh) | 2019-12-26 |
| JP7430656B2 (ja) | 2024-02-13 |
| SG11202012858QA (en) | 2021-02-25 |
| US20210261546A1 (en) | 2021-08-26 |
| EA202190036A1 (ru) | 2021-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6986032B2 (ja) | Ｊａｋ阻害剤としてのピロロピリミジン化合物の結晶 | |
| JP2024012540A (ja) | Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用 | |
| JP2022071072A (ja) | （ｓ）－７－（１－アクリロイルピペリジン－４－イル）－２－（４－フェノキシフェニル）－４，５，６，７－テトラ－ヒドロピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミドの結晶形、その調製、及びその使用 | |
| TW202309027A (zh) | 作為ｐａｒｐ抑制劑的化合物 | |
| CN113993873A (zh) | 用于治疗癌症的egfr抑制剂 | |
| US20100204246A1 (en) | 5-aminopyrazol-3-yl-3h-imidazo (4,5-b) pyridine derivatives and their use for the treatment of cancer | |
| CN109689641B (zh) | 一种取代的2-氢-吡唑衍生物的晶型、盐型及其制备方法 | |
| MXPA06001758A (es) | Anilino purinas sustituidas en la posicion 6 utiles como inhibidores de rtk. | |
| WO2016011979A1 (zh) | 2，4-二取代7H-吡咯并[2，3-d]嘧啶衍生物、其制法与医药上的用途 | |
| KR102768666B1 (ko) | Cdk4/6의 활성을 억제하기 위한 화합물의 결정 형태 및 그것의 용도 | |
| JP2018503634A (ja) | サイクリン依存性タンパク質キナーゼインヒビターのヒドロキシエチルスルホン酸塩、その結晶形およびその製造方法 | |
| CN111763215A (zh) | 一种具有含氮杂环结构的化合物及其制备方法和用途 | |
| CN109593102B (zh) | 一种氘代二苯氨基嘧啶类化合物的制备方法及其晶型 | |
| CA3104365C (en) | Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof | |
| CN102666528B (zh) | 晶体cdc7 抑制剂盐 | |
| KR20220159457A (ko) | Fgfr4 억제제의 염 형태, 결정 형태 및 그 용도 | |
| CN120289432B (zh) | 一种具有极光激酶b和表皮生长因子受体双重抑制作用的喹啉类化合物及用途 | |
| EA043251B1 (ru) | Кристаллическая форма соединения для ингибирования активности cdk4/6 и ее применение | |
| HK40037648A (en) | Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof | |
| HK40037648B (en) | Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof | |
| US20210340142A1 (en) | Salt form and crystal form of novel azatricyclic compound and use thereof | |
| WO2021249450A1 (zh) | 酪氨酸激酶抑制剂的盐型、晶型、药物组合物及其用途 | |
| TW202342041A (zh) | 一種藥物組合物及所含活性成分化合物的製備方法 | |
| CN116836177A (zh) | 一种蛋白激酶抑制剂的枸橼酸盐、其晶型、制备方法和用途 | |
| KR20070017938A (ko) | Ｒｔｋ 억제제로서의 6-치환된 아닐리노 퓨린 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R13-asn-PN2301 St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |